Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Nov;81(21):6861–6865. doi: 10.1073/pnas.81.21.6861

5 alpha-Cholest-8(14)-en-3 beta-ol-15-one lowers serum cholesterol and induces profound changes in the levels of lipoprotein cholesterol and apoproteins in monkeys fed a diet of moderate cholesterol content.

G J Schroepfer Jr, B C Sherrill, K S Wang, W K Wilson, A Kisic, T B Clarkson
PMCID: PMC392032  PMID: 6593730

Abstract

5 alpha-Cholest-8(14)-en-3 beta-ol-15-one has been found to have significant hypocholesterolemic activity upon oral administration at a daily dosage of 75 mg/kg of body weight to Rhesus monkeys fed a diet of moderate cholesterol (Chol) content [0.19 mg/kcal (1 cal = 4.184 J) of diet]. The reductions in total serum Chol levels (mean, -41%) were associated with even more striking reductions (mean, -61%) in the levels of low density lipoprotein (LDL) plus very low density lipoprotein (VLDL) Chol and also with increases in high density lipoprotein (HDL) Chol levels (mean, +61%). The mean increase in HDL Chol was 33 mg/dl. In one animal, that with the lowest pretreatment HDL Chol level, the extent of the rise was 49 mg/dl (+120%). These changes were associated with reductions in the % of total serum Chol associated with LDL/VLDL, in the ratios of total Chol to HDL Chol and of LDL/VLDL Chol to HDL Chol, and in the levels of LDL protein. The 15-ketosterol also increased the % of total Chol associated with HDL, increased the level of HDL protein, and induced a shift in the HDL profile to one in which the HDL2 species was the predominant species. All of these changes are those generally considered desirable for the treatment and/or prevention of atherosclerosis.

Full text

PDF
6861

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARR D. P., RUSS E. M., EDER H. A. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951 Oct;11(4):480–493. doi: 10.1016/0002-9343(51)90183-0. [DOI] [PubMed] [Google Scholar]
  2. Ballantyne F. C., Clark R. S., Simpson H. S., Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism. 1982 May;31(5):433–437. doi: 10.1016/0026-0495(82)90230-x. [DOI] [PubMed] [Google Scholar]
  3. Fraser G. E., Anderson J. T., Foster N., Goldberg R., Jacobs D., Blackburn H. The effect of alcohol on serum high density lipoprotein (HDL). A controlled experiment. Atherosclerosis. 1983 Mar;46(3):275–286. doi: 10.1016/0021-9150(83)90178-8. [DOI] [PubMed] [Google Scholar]
  4. Gofman J. W., Young W., Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966 Oct;34(4):679–697. doi: 10.1161/01.cir.34.4.679. [DOI] [PubMed] [Google Scholar]
  5. Gordon T., Kannel W. B., Castelli W. P., Dawber T. R. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med. 1981 Aug;141(9):1128–1131. [PubMed] [Google Scholar]
  6. Kannel W. B., Castelli W. P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979 Jan;90(1):85–91. doi: 10.7326/0003-4819-90-1-85. [DOI] [PubMed] [Google Scholar]
  7. Kannel W. B. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983 Aug 22;52(4):9B–12B. doi: 10.1016/0002-9149(83)90649-5. [DOI] [PubMed] [Google Scholar]
  8. Kavanagh T., Shephard R. J., Lindley L. J., Pieper M. Influence of exercise and life-style variables upon high density lipoprotein cholesterol after myocardial infarction. Arteriosclerosis. 1983 May-Jun;3(3):249–259. doi: 10.1161/01.atv.3.3.249. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Levy R. I. Cholesterol, lipoproteins, apoproteins, and heart disease: present status and future prospects. Clin Chem. 1981 May;27(5):653–662. [PubMed] [Google Scholar]
  11. Miller L. R., Pajewski T. N., Schroepfer G. J., Jr Inhibitors of sterol synthesis. Studies of in vitro effects of C27 15-oxygenated sterols on sterol synthesis in cell free homogenates of rat liver. J Biol Chem. 1982 Mar 10;257(5):2412–2419. [PubMed] [Google Scholar]
  12. Monger D. J., Parish E. J., Schroepfer G. J., Jr 15-Oxygenated sterols. Enzymatic conversion of [2,4]3H]5 alpha-cholest-8(14)-en-3 beta-ol-15-one to cholesterol in rat liver homogenate preparations. J Biol Chem. 1980 Dec 10;255(23):11122–11129. [PubMed] [Google Scholar]
  13. Parish E. J., Spike T. E., Schroepfer G. J., Jr Sterol synthesis. Chemical synthesis of 3beta-benzoyloxy -14alpha, 15alpha-epoxy-5alpha-cholest-7-ene, a key intermediate in the synthesis of 15-oxygenated sterols. Chem Phys Lipids. 1977 Apr;18(3-4):233–239. doi: 10.1016/0009-3084(77)90011-1. [DOI] [PubMed] [Google Scholar]
  14. Patsch W., Patsch J. R., Kostner G. M., Sailer S., Braunsteiner H. Isolation of subfractions of human very low density lipoproteins by zonal ultracentrifugation. J Biol Chem. 1978 Jul 25;253(14):4911–4915. [PubMed] [Google Scholar]
  15. Patsch W., Schonfeld G., Gotto A. M., Jr, Patsch J. R. Characterization of human high density lipoproteins by zonal ultracentrifugation. J Biol Chem. 1980 Apr 10;255(7):3178–3185. [PubMed] [Google Scholar]
  16. Pinkerton F. D., Izumi A., Anderson C. M., Miller L. R., Kisic A., Schroepfer G. J., Jr 14 alpha-Ethyl-5 alpha-cholest-7-ene-3 beta,15 alpha-diol, a potent inhibitor of sterol biosynthesis, has two sites of action in cultured mammalian cells. J Biol Chem. 1982 Feb 25;257(4):1929–1936. [PubMed] [Google Scholar]
  17. Redgrave T. G., Roberts D. C., West C. E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975 May 12;65(1-2):42–49. doi: 10.1016/0003-2697(75)90488-1. [DOI] [PubMed] [Google Scholar]
  18. SCHROEPFER G. J., Jr Lipid factors in atherosclerosis. N Engl J Med. 1957 Dec 19;257(25):1223–contd. doi: 10.1056/NEJM195712192572506. [DOI] [PubMed] [Google Scholar]
  19. Schroepfer G. J., Jr, Monger D., Taylor A. S., Chamberlain J. S., Parish E. J., Kisic A., Kandutsch A. A. Inhibitors of sterol synthesis. Hypocholesterolemic action of dietary 5alpha-cholest-8(14)-en-3beta-ol-15-one in rats and mice. Biochem Biophys Res Commun. 1977 Oct 24;78(4):1227–1233. doi: 10.1016/0006-291x(77)91424-3. [DOI] [PubMed] [Google Scholar]
  20. Schroepfer G. J., Jr, Parish E. J., Chen H. W., Kandutsch A. A. Inhibition of sterol biosynthesis in L cells and mouse liver cells by 15-oxygenated sterols. J Biol Chem. 1977 Dec 25;252(24):8975–8980. [PubMed] [Google Scholar]
  21. Schroepfer G. J., Jr, Parish E. J., Kisic A., Jackson E. M., Farley C. M., Mott G. E. 5 alpha-Cholest-8(14)-en-3 beta-ol-15-one, a potent inhibitor of sterol biosynthesis, lowers serum cholesterol and alters distributions of cholesterol in lipoproteins in baboons. Proc Natl Acad Sci U S A. 1982 May;79(9):3042–3046. doi: 10.1073/pnas.79.9.3042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shandilya L. N., Clarkson T. B. Hypolipidemic effects of gossypol in cynomolgus monkeys (Macaca fascicularis). Lipids. 1982 Apr;17(4):285–290. doi: 10.1007/BF02534943. [DOI] [PubMed] [Google Scholar]
  23. Wood P. D., Haskell W. L., Blair S. N., Williams P. T., Krauss R. M., Lindgren F. T., Albers J. J., Ho P. H., Farquhar J. W. Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism. 1983 Jan;32(1):31–39. doi: 10.1016/0026-0495(83)90152-x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES